REVIEW

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Matthew N. Hurley*, Miguel Câmara# and Alan R. Smyth*

ABSTRACT: Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed.

KEYWORDS: Antibiotic resistance, antibiotic treatment, cystic fibrosis and chronic infections, Pseudomonas

Concern regarding the impact of antibiotic resistance has led the European Commission to develop an action plan against the rising threat, priority is given to mitigating the development of antibiotic resistance through appropriate use, prevention of infection and developing effective antimicrobials [1]. In a paired surveillance report by the European Centre of Disease Prevention and Control, reporting on resistance trends of the top seven bacterial pathogens of importance to human health, Pseudomonas aeruginosa is detailed as being of particular concern due to its ubiquity and intrinsic tolerance to many antibiotics [2]. Many patients have increased susceptibility to P. aeruginosa infections including those with chronic lung conditions such as cystic fibrosis (CF), bronchiectasis and chronic obstructive pulmonary disease [3]; individuals who are immunosuppressed, those receiving intensive care and those who have indwelling catheters [4].

Of those patients with CF, those with chronic pulmonary infection with P. aeruginosa suffer a more rapid deterioration in lung function, greater morbidity and a shorter life expectancy [5]. Repeated prolonged courses of broad-spectrum antibiotics lead to the selection of increasing antibiotic tolerant and resistant strains [6]. Although infection with P. aeruginosa may be eradicated if treatment is commenced early [7], no antibiotics are able to eradicate an established chronic P. aeruginosa infection and there are no such agents on the horizon [8]. A new paradigm for the management of chronic pulmonary infection with P. aeruginosa in CF is clearly needed. Antibiotic adjuvants, agents that act alongside a co-administered antibiotic, potentiating its action, may offer a future strategy. We recently published a Cochrane review [9] and found that few such interventions had been assessed in rigorous clinical trials and so could not recommend their use. There are, however, numerous of these novel strategies under development some of which are reaching clinical trials. This review will evaluate the opportunities these strategies may present and consider when such therapeutic approaches may be available for our patients.
and protease production, appear not to be predictive of persistence compared with strains that are successfully eradicated [11]. Instead a combination of host-pathogen factors may be important in the conversion to chronic infection rather than bacterial factors in isolation, in contrast to the situation with non-CF bronchiectasis.

The biofilm mode of growth is associated with a mucoid phenotype of *P. aeruginosa* [12]. Individuals with CF who are chronically infected with mucoid organisms have a more rapid decline in clinical status compared with those with non-mucoid *P. aeruginosa* who in turn decline more rapidly than those without infection [13].

There is significant phenotypic variation between *P. aeruginosa* strains found to infect the CF lung both within [14] and between [15] individuals. Rapid mutations may occur in subsets of bacteria within individuals that provide adaptation for chronic infection and are linked to the development of antibiotic resistance [15]. The innate antibacterial tolerance of *P. aeruginosa* provides significant therapeutic challenges but this, accompanied by its modest nutritional demands and ability to use both aerobic and anaerobic metabolism, makes it a versatile opportunistic pathogen. The biofilm mode of growth provides a significant challenge for therapy as even when antibiotics are able to penetrate the biofilm, the combination of oxygen limitation and low bacterial metabolic activity result in limited bacterial killing [16] with a core of inactive “persister” cells that are uniquely tolerant to antibiotics but can re-populate the biofilm once administration of an antibiotic ceases [17].

In the CF lung, a lack of functioning CF transmembrane regulator (CFTR) in the apical membrane of the respiratory epithelial cell results in an environment that is favourable to *P. aeruginosa*. Physical effects of thick secretions, dehydrated epithelial surfaces and accompanying mucus plugging allow the organism to become pathogenic [4], this organism exerts a significant burden on the well-being of patients with CF.

**RECENT ADVANCES IN ANTIBIOTIC THERAPIES**

New antibiotic formulations have been developed over recent years and some are within the developmental pipeline. Tobramycin inhalation solution (TIS) has been introduced for the long-term management of chronic *P. aeruginosa* infection, with a Cochrane review [20] suggesting some benefit from TIS in terms of lung function and pulmonary exacerbation rate but also concern regarding an increase in antibiotic resistance. A recent registry study examining data from the Cystic Fibrosis Foundation’s Patient Registry has suggested that TIS use is associated with reduced mortality [21]. TIS has also been demonstrated to be effective in delaying re-infection in those with early *P. aeruginosa* infection [22]. A dry powder formulation of tobramycin for inhalation has been developed that does not require a nebuliser and so appears to be more convenient, but as effective as TIS [23, 24]. It is suggested that this may improve adherence to treatment. Aztreonam lysine has recently been approved for inhalation for those with *P. aeruginosa* infection the benefit of which appears to be good sputum penetration, delayed time to next exacerbation and improved lung function [25].

Antibiotics in development include liposomal preparations of amikacin and ciprofloxacin [26] and the first trial of a levofloxacin inhalation solution which was recently reported with favourable results [27]. A new family of peptidomimetics has generated excitement as early *in vitro* and animal models suggest potency but also specificity for *P. aeruginosa* [28].

**ANTI-VIRULENCE STRATEGIES**

Much of the organism’s capacity for virulence, antibiotic resistance and evasion of the host immune system is controlled by complex chemical signalling mechanisms. These mechanisms offer the potential for exploitation as therapeutic targets in the development of novel antibacterial agents (table 1).

**QS inhibition**

*P. aeruginosa* regulates much of its virulence via quorum sensing (QS). QS is a mechanism by which individual bacteria communicate with each other through the production and detection of small signal molecules. The concentration of signal molecules within their environment increases in line with the number of bacteria within the colony producing that signal. Eventually this concentration reaches a threshold and activates virulence gene expression within the bacterial community in a coordinated manner [47]. These signals may also be perceived by other bacterial species, resulting in competition for the same niche [31] and even eukaryotic host cells resulting in cross-kingdom signalling [32, 46].

*P. aeruginosa* uses at least three QS signalling pathways (fig. 1). The Las and Rhl pathways utilise the N-acylhomoserine lactones (AHLs) N-(3-oxo-dodecanoyl)-L-homoserine lactone (3OC12-HSL) and N-butanoyl-L-homoserine lactone (C4-HSL), respectively [48]. The alkyquinoline pathway uses 2-heptyl-3-hydroxy-4-quinolone, also known as the pseudomonas quinolone signal (PQS), and its biosynthetic precursor 2-heptyl-4-quinolone (HHQ) [49]. These QS molecules are released into the environment by free diffusion (C4-HSL) [50], via efflux pumps (3OC12-HSL) [50] and embedded within micro-vesicles (PQS) [51]. Once the signal molecule concentration inside cells reaches a threshold it binds to its cognate transcriptional factor; 3OC12-HSL to LasR, C4-HSL to RhlR and PQS/HHQ to PqsR. The subsequent activation results in the induction of expression of multiple virulence genes and the upregulation of the signal biosynthetic genes resulting in the production of more signal (autoinduction) [52].

QS regulates the production of multiple virulence products (table 1) that includes rhamnolipid (inhibiting the function of host polymorphonuclear leukocytes (PMNLs)). Wild type biofilms are resistant to tobramycin and the action of PMNLs however QS-deficient biofilms are significantly more sensitive to the action of tobramycin and PMNLs [53]. While QS has a significant role in the formation of antibiotic resistant *P. aeruginosa* biofilms with QS-negative mutants forming abnormal, flat and biocide-sensitive biofilms [54], the addition of PQS substantially enhances biofilm development [55]. The pivotal role of QS in the formation of biofilms is demonstrated in a mouse foreign body model of
infection whereby silicone implants were infected with wild type and QS-deficient bacteria. The QS-deficient bacteria were rapidly cleared compared to the wild type bacteria which were only cleared after treatment with a QS inhibitor [56].

QS, pivotal for the regulation of virulence in *P. aeruginosa*, is therefore a prime therapeutic target. QS inhibition (or “quorum quenching”) of AHL signalling pathways can be achieved at different levels including the interference of signal generation, the degradation of signal molecules, preventing their accumulation, and the antagonism of the signals mode of action [57]. In the case of signal degradation, a number of enzymes of bacterial origin, capable of degrading AHL molecules and attenuating bacterial virulence gene expression have been identified [57].

QS signal molecules have been identified in the sputa of patients with CF and *P. aeruginosa* infection [58, 59]. Many potential QS inhibitors (QSI) which show similarities to the signal molecules have been identified by high-throughput technologies. Quorum quenching activity has been found in a number of foods including chamomile, carrot and garlic but also in algae. Some of the most potent candidates, such as algal furanones, are toxic to man but provide the chemical basis for the development of non-toxic QSIs [60, 61].

Garlic (*Allium sativum*) is one of the more potent naturally occurring QSIs. Garlic extracts have been shown to increase the susceptibility of *P. aeruginosa* biofilms to antibiotics in vitro and promote clearance of *P. aeruginosa* in a chronic mouse infection model [62]. However, direct extrapolation from an animal model to man is not possible because doses administered to mice in this model were considerably greater than those that could be tolerated by humans [62]. In a small pilot randomised controlled trial of a commercial garlic formulation in adults and children with CF and chronic *P. aeruginosa* infection, there was a nonsignificant improvement in clinical parameters and it was possible to detect QS molecules in the plasma and sputa of these patients indicating QS activity [63]. Hence the current

| TABLE 1 | Virulence approaches by *Pseudomonas aeruginosa*, their role in pathogenicity and opportunities for intervention. |
|-----------------|---------------------------------------------------------------------------------|----------------------------------|
| **Virulence approaches** | **Mechanism of action/activity** | **Therapeutic strategies** |
| Alginate biofilm* | Biofilm formation [29] | Alginate lyase [30] |
| Quorum sensing* [31] | Coordination of virulence factor production | QS inhibitors |
| Phenotypic transfer and variability | Immune modulation [32] | | |
| PII* | | | |
| RND efflux pumps* [36] | Antibiotic removal [37] | Efflux pump inhibitors |
| Lectin* | | | |
| Flagella | Motility [34] | Immune modulation [40] |
| Immune modulation* [32] | AHLL/AQ signal | QS inhibition |
| Rhamnolipid* [41] | Biosurfactants – diffusible nutrition | QS inhibition |
| Iron sequestration* | Pyoverdin | QS inhibition |
| Enzymes | Elastases | | |
| Antibiotic modifying | Phospholipase | | |
| Toxins | Lecithinase (alkaline protease) | 1-glactamase inhibitors |
| Host-cardiovascular effects [46] | Aminoglycoside-modifying enzymes | | |
| | Lipopolysaccharide (endotoxin) | Immunotherapy and Immunisation [44] |
| | Exotoxin A | Antibody to secretion system apparatus [45] |
| | Exoenzyme S | | |

QS: quorum sensing; AHLL: N-acylhomoserine lactone; AQ: alkylquinoline; PMNL: polymorphonuclear leukocyte; PQS: *Pseudomonas* quinolone signal. #: quorum sensing regulated factor.
The challenge is to identify effective strategies to translate QSIs from natural sources to use in the clinic.

Commonly used antibiotics including azithromycin, ceftazidime and ciprofloxacin have been shown to have a negative impact on QS-dependent virulence factor production [64]. Interestingly, azithromycin acts as a QSI at concentrations below its minimum inhibitory concentration [64, 65]. A murine chronic infection model has demonstrated significantly more clearance in those treated with azithromycin compared with control [65].

**Lectin inhibitors**

Lectins are outer membrane proteins which recognise sugar residues and allow bacterial cells to cross link, aggregate and so form the architecture of the biofilm [38, 66]. Lectins may also interfere with normal ciliary beating in the human airway [39] and form another barrier to host-mediated clearance of the organism.

The two specific lectins, LecA and LecB have fucose-specific and galactose-specific binding sites and so may be blocked by competitive inhibitors (fucose and galactose moieties, respectively). Studies performed in vitro show that these inhibitors either on their own or accompanied by an antibiotic, facilitate dissolution of biofilms or prevent their formation [66–68].

A small randomised trial in CF patients, without a control group, demonstrated a positive trend towards improvement in those that received fucose/galactose inhalation treatment [69]. Patients with chronic *P. aeruginosa* infection were recruited during an infective exacerbation and randomised to receive either inhalation of sugars alone or inhalation accompanied by intravenous antibiotics. Both groups demonstrated a significant reduction in sputum *P. aeruginosa*’s colony forming units and tumour necrosis factor-α levels. More recently, multivalent dendrimers with these sugars attached to them have shown higher affinities than monovalent fucose, showing potential as therapeutic agents [70].

**Iron chelation**

Iron metabolism in the respiratory tract is complex [71] and only available as free iron in minute quantities in the healthy respiratory epithelium.

---

**FIGURE 1.** Quorum sensing (QS) pathways of *Pseudomonas aeruginosa*. *P. aeruginosa* uses N-acylhomoserine lactones (AHLs) and alkylquinolines (AQ) mediated QS systems to control the production of virulence factors and the interaction with the host. The balance between these signalling mechanisms is also a key determinant in biofilm formation. 3OC12-HSL: N-(3-oxo-dodecanoyl)-L-homoserine lactone; C4-HSL: N-butanoyl-L-homoserine lactone; HHQ: 2-heptyl-4-quinolone; PQS: *Pseudomonas* quinolone signal.
lung as it is normally bound by ferritin and transferrin. However, compared with non-CF sputa, the sputa of patients with CF is a rich iron source, and correlates with chronic *P. aeruginosa* infection [72]. The acquisition of iron is essential for the survival of this bacterium. It sequesters iron from its environment predominantly, but not exclusively [73] using the siderophores pyoverdin and pyochelin [74]. The human innate immune system has developed to recognise and block biofilm development through the action of lactoferrin, at sub-bacterial concentrations [75]. Lactoferrin chelates iron prompting the bacteria to increase motility, rather than form a biofilm. However, in the CF airway the affinity of these siderophores for iron is higher than that of serum proteins and so the protein-bound iron may be sequestered directly by the action of pyoverdin [76] or liberated by proteolytic cleavage [77], see Lamont et al. [78] for a detailed review.

Gallium and desferrioxamine are both in clinical use for non-bacterial indications. However their iron chelation activity is of interest as this may interfere with bacterial iron metabolism. Gallium-gentamicin liposomal co-encapsulation preparations have been shown to enhance *in vitro* activity of gentamicin against CF clinical isolates of *P. aeruginosa* [43]. A pharmacokinetic and safety study in patients with CF is underway (Clinicaltrial.gov identifier NCT01093521). Combinations of administration of desferrioxamine and tobramycin have been shown *in vitro* to significantly reduce biomass of preformed biofilms and prevent the formation of biofilm on CF epithelial cells [79].

**ANTI-RESISTANCE STRATEGIES**

**Efflux pumps**

Efflux pumps allow the organism to regulate their internal environment by removing toxic substances, including antibiotics [36], metabolites and QS signal molecules [50]. They are also implicated in host invasion. Elements of multidrug resistance are attributed to five families of efflux pumps of which *P. aeruginosa* has many of interest within the resistance nodulation division (RND) family which are implicated in resistance to many antibiotics including ciprofloxacin, ceftazidime and tobramycin [80].

Some of the efflux pumps expressed by *P. aeruginosa* are only active under specific growth conditions, such as those encountered in biofilms [81]. Indeed, QS is partly dependent upon efflux, as the signal molecule 3OC12-HSL is not diffusible across the cell membrane and requires active transport involving efflux pumps [50]. Findings in clinical strains have been inconsistent as over-expression of certain efflux pumps increases antibiotic resistance [82], but can also be associated with reduced virulence [83]. This may in part be related to the effects upon QS whereby increased efflux activity may increase the transport of efflux pump-dependent QS molecules (pro-virulent) but other QS molecules may be exported from within a cell preventing the concentration of these molecules reaching a quorum (and so inhibit virulence). Interestingly, these attenuated strains over-expressing efflux pumps formed better biofilms [83]. It would appear that antibiotic resistance and virulence may have competing costs for the organism and that intervention at the level of the efflux pump may have varied consequences.

The use of efflux pump inhibitors (EPIs) have revealed that intrinsic antibiotic resistance may be overcome, acquired resistance may be reversed, and the emergence of new resistant strains to a co-administered antibiotic may be reduced [84]. Indeed there are EPIs which can ameliorate fluoroquinolone resistance in clinical strains [37]. A screen for EPI candidates revealed Phe-Arg-β-naphthylamide acted as an EPI [77] however progression along the drug development pipeline was halted due to phototoxicity [85]. While existing drugs, such as selective serotonin re-uptake inhibitors, in the case of *Staphylococcus aureus*, appear to have EPI activity, an agent that acts upon *P. aeruginosa* has not been published [85]. Mpex Pharmaceuticals (San Diego, CA, USA) are currently developing an EPI agent in partnership with GlaxoSmithKline due to the potential of this type of treatment in the clinic. Mpex Pharmaceuticals have also been developing levofloxacin inhalation solution, the efficacy of which they have shown is increased eight-fold in the presence of a candidate EPI [86] and so it is conceivable that the product of the EPI development would be co-administered with this.

Agents that reduce the effect of efflux pumps may be useful therapeutically and result in a more effective action of antibiotics. However, such an approach is likely to be complex given the opposing actions of virulence, growth and resistance [83] and the variety of efflux pumps hosted by *P. aeruginosa* [36].

**Genetic “inhibitors” of resistance mechanisms**

Antisense or antigene strategies have been proposed as inhibitors of resistance mechanisms at the nucleic acid level, targeting DNA and mRNA to prevent transcription and/or translation of specific genes [33]. By doing so the expression of the antibiotic resistance gene is blocked and the gene product conferring resistance is not produced.

Such an approach has been successful *in vitro* in reverting resistant strains to sensitive phenotypes. Delivery of the antisense agent to the site of infection is a challenge that may be overcome by linking the antisense molecule to a cell-permeabilising peptide. This has been achieved with *Escherichia coli* [87] but when considering the impermeability of *P. aeruginosa* this may be quite a different undertaking. Although at a prospecting stage a delivery strategy using a bacteriophage vector [33] or a conjugate of an agent linked to a delivery peptide, as has recently been described in the investigation of activity of such an agent upon antibiotic resistant Gram-negative and Gram-positive bacterial species, may be possible [88].

**Bacteriophages**

Bacteriophages are naturally-occurring viruses that infect bacterial cells, in many cases causing lysis of the bacterium. They are present in all environments and we are continually exposed to them. The advantages of using bacteriophages to kill bacteria are that only a specific bacterium will be killed, the viruses replicate at the site of the infection and few side-effects have been described [89].

Studies using *P. aeruginosa in vitro* bacterial biofilms have been encouraging, demonstrating the ability of the phages to penetrate the biofilm and kill the bacteria [90]. In a murine model of intraperitoneal *P. aeruginosa* infection, a non-replicating phage yielded a 70% survival rate at day 7 compared with a 20% survival at day 2 in untreated mice [91].
Bacteriophage therapy has been used routinely in Tblisi, Georgia although little peer-reviewed data are available [92]. A recent human clinical trial of a bacteriophage treatment of refractory *P. aeruginosa*-related chronic otitis externa has further demonstrated potential benefit [93]. This randomised double-blind placebo-controlled trial using a six phage strain preparation recruited patients with previously chronic and unresponsive otitis externa. These patients were selected as their infections were confirmed to exhibit *in vitro* bacterial sensitivity to the phage preparation. Significant reductions in patient and physician evaluation scores were observed in all domains for the treated group which was directly correlated with a significant decrease in *P. aeruginosa* counts. The mean duration of bacteriophages replication was 23 days in the treated group and in those patients that completely cleared their *P. aeruginosa* infection no bacteriophages could be isolated thereafter. A randomised clinical trial assessing the efficacy of bacteriophage therapy for venous leg ulcers has recently completed and results are awaited [94].

There are multiple challenges with translating the promising *in vitro* studies with bacteriophages to widespread clinical use. While the recent clinical trials indicate a move of regulatory authorities to consider and approve such studies, gaining regulatory authority for widespread clinical use will be difficult. There are also significant technical challenges with phage selection, purification, storage and sterility control [95]. Difficulties associated with phage therapy, however, include their specificity for individual bacterial strains, preventing the use of a single phage to treat infections involving multiple strains. In the chronic otitis media study, of those that were screened, 86.2% were sensitive to the six-phage mix. Phage virulence and dose, as well as the challenges posed by the immune system of the mammalian host must also be considered for this kind of treatment [90]. These are of particular relevance to pulmonary infection in CF. Possible hazards must be considered when evaluating the potential therapeutic use of bacteriophages, such as the possibility of the infected organism acquiring virulence traits from the phage, as has been demonstrated recently [96].

**Endolysins**

Bacteriophages produce endolysins to exert their hydrolase action on the peptidoglycan cell wall resulting in the lysis of the organism. The potential of endolysins in the treatment of infection has been tested in animal disease models and found to successfully clear *Streptococcus pneumoniae* from colonised mucosal surfaces [97].

While translation of this may be less complicated in Gram-positive bacteria, the challenge of delivering an endolysin, or so-called “enzymbiotic” through the less permeable outer membrane of Gram-negative bacteria is more complex [98]. However, in combination with an agent administered to penetrate the outer membrane, such an approach could be possible, yet very early in development [99].

**Immunisation and immunotherapy**

Prevention of primary infection by immunisation is an ambitious aim considering the diversity of mechanisms used by the organism to cause disease and the variability with which they are expressed. The use of exotoxin A toxoid and lipopolysaccharide as antigens have shown reduced mortality in murine models [44]. Other strategies involving immunogenic bacterial proteins, including flagellin, the highly immunogenic protein that comprises the flagellum, are currently in development. While there have been some clinical trials of vaccine preparations published suggesting a positive effect, few are of high quality in terms of randomisation and design. Three of these trials were included in a Cochrane review [100] involving 996 patients with a follow-up of between 2 and 12 yrs where the authors concluded that vaccination cannot currently be recommended.

While immunisation strategies continue to be developed, immunotherapy also offers a similar approach to increase the efficacy of conventional antibiotics by artificially stimulating the immune system. Immunotherapy studies are largely marred by similar criticisms of either no or poor randomisation and non-contemporaneous controls. However the authors of the currently available studies suggest that immunoglobulin (Ig)Y prophylaxis could increase the time to first infection, reduce the number of infection events, reduce the time to established chronic infection and delay the conversion to a mucoid strain [101]. These results have prompted its licensing in Sweden [102] and its designation as an orphan drug. A Phase III double blind randomised controlled trial of 180 patients is underway (Clinicaltrial.gov identifier NCT01455675) recruiting those with *P. aeruginosa* infection with the primary outcome measure being time from start of treatment to the first isolation of *P. aeruginosa* from sputum culture or throat swab. The completion of this study is expected in December 2014. A phase IIA open pilot trial of a monoclonal anti-lipopolysaccharide IgM antibody in those with ventilator associated pneumonia suggested that such a therapy is safe and suggested a degree of efficacy in the small number of patients treated [103].

Antibodies have also been used against specific elements of the type III secretion apparatus of *P. aeruginosa*. These have ameliorated infection in a mouse pneumonia model with a subsequent reduction in mortality and bacterial load [104]. Preliminary reports of a phase I/II study in patients with CF suggested a dose-dependent reduction in sputum inflammatory markers although the full report is awaited [45] as are results from a phase I/II study of patients with ventilator associated pneumonia.

**Innate immunity supplementation**

A component of the airway response to bacteria is the generation of hypothiocyanite (OSCN⁻), which is bactericidal. However, the generation of this is defective in patients with CF [105]. Preliminary data suggest an impressive reduction in bacterial growth *in vitro* and in a murine model of infection with a nebulised OSCN⁻/lactoferrin preparation [106]. This preparation (Meveol) has recently been granted orphan drug status.

**SUMMARY**

*P. aeruginosa* exploits multiple mechanisms to elude the host immune response and the action of conventional antibiotics. Frequent and prolonged courses of broad spectrum *i.v.* antibiotics encourage the emergence of resistance.

Conventional antibiotics, such as azithromycin, may have some efflux and QS inhibitory effects which may invigorate work to develop antibiotics of existing classes that have additional effects [107]. However the longevity of such an approach is likely to be
limited as the organism evolves to overcome such an effect. With the exception of a new generation of peptidomimetic antibiotics early in the discovery process [28], new antibiotics exploiting novel mechanisms of action do not appear to be in the pipeline. Consequently, the targets discussed above may act as useful adjuvants, increasing the effectiveness of antibiotics at our disposal. The optimal timing for the use of these agents remains uncertain, however, it is likely that some approaches may be more suited to prophylaxis, while others may prolong the opportunity for eradication of early infection or may enable a treatment strategy for chronic infection. However, it will be some time before such treatments reach the bedside. The novel nature of each of these approaches suggests that clinical application of these therapies may be slow and progress limited by a lack of experience of similar approaches with which to satisfy regulatory bodies. Furthermore, the limited markets for specific CF-applied therapies mean that biotechnology companies may limit interest in strategies without wider application. Nevertheless, novel approaches are required to limit P. aeruginosa’s resistance to antibiotics and the host immune system so that treatment of this versatile organism may be successful.

SUPPORT STATEMENT
M.N. Hurley is funded by a Wellcome Trust Clinical Research Training Fellowship (WT092295MA).

STATEMENT OF INTEREST
A statement of interest for A.R. Smyth can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

ACKNOWLEDGEMENTS
A.R. Smyth is a member of the Cochrane Cystic Fibrosis and Genetic Disorders Group and MCRN-East (part of the National Institute for Health Research, Medicines for Children Research Network).

REFERENCES
1. European Commission and Directorate General for Health and Consumers. Communication from the Commission to the European Parliament and the Council Action plan against the rising threats from Antimicrobial Resistance. 2011 Contract No. COM (2011) 748.
2. European Centre of Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, ECDC, 2011.
3. Garcia-Vidal C, Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34: 1072–1078.
4. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171: 1209–1223.
5. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91–100.
6. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1999; 33: 919–926.
7. Langton-Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD004197.
8. Talbot G, Bradley J, Edwards JJ, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657–668.
9. Hurley MN, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev 2010; 10: CD008037.
10. Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother 2010; 65: 2373–2375.
11. Tramper-Stranders GA, van der Ent CK, Molin S, et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clinical Microbiol Infect 2012; 18: 567–574.
12. Drenkard E, Ausubel F. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740–743.
13. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581–588.
14. Fothergill JL, Mowat E, Ledson MJ, et al. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol 2010; 59: 472–481.
15. Oliver A, Cantor R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251–1253.
16. Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47: 317–323.
17. Keren I, Kaldalu N, Spoering A, et al. Persistser cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230: 13–18.
18. Zar H, Saiman L, Quittell L, et al. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995; 126: 230–233.
19. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 94: 12088–12093.
20. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011; 3: CD001821.
21. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012; 47: 44–52.
22. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286–291.
23. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10: 54–61.
24. Konstan MW, Flume PA, Brockhous F, et al. Safety and efficacy of tobramycin inhalation powder (TIPTM) in treating cystic fibrosis patients infected with Pseudomonas aeruginosa (Pa). J Cyst Fibros 2010; 9: Suppl. 1, S22.
25. McCoy KS, Quittner AL, Gernmann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921–928.
26. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295–315.
32 Telford G, Wheeler D, Williams P, et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998; 66: 36–42.

33 Woodford N, Wareham DW, on behalf of the UK Antibacterial Antisense Study Group. Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemother 2009; 63: 225–229.

34 Barken K, Pamp S, Yang L, et al. Roles of type IV pili, flagellum-mediated motility and extracellular matrix in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms. Environ Microbiol 2008; 10: 2331–2343.

35 van Schaik EJ, Giltner CL, Audette GF, et al. DNA Binding: a novel function of Pseudomonas aeruginosa type IV pili. J Bacteriol 2005; 187: 1455–1464.

36 Allibert-Franco S, Pradines B, Mahmoud A, et al. Efflux mechanism, an attractive target to combat multidrug resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr Med Chem 2009; 16: 301–317.

37 Coban A, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004; 50: 22–26.

38 Tieler D, Hacker S, Loris R, et al. Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology 2005; 151: 1313–1323.

39 Adam E, Mitchell B, Schumacher D, et al. Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of the bacterial quorum sensing signal molecule, N-(3-oxododecanoyl)-L-homoserine lactone in conscious, normal and endotoxaemic rats. Br J Pharmacol 2001; 133: 1047–1054.

40 Suqua C, Winans SC, Greenberg EP. Censys and consensus in bacterial ecosystems the LuxR-LuxI family of quorum-sensing transcriptional regulators. Annu Rev Microbiol 1996; 50: 727–751.

41 Williams P, Winzer K, Chan WC, et al. Look who’s talking: communication and quorum sensing in the bacterial world. Philos Trans R Soc Lond B Biol Sci 2007; 362: 1119–1134.

42 Piggle SP, Cornéolis P, Williams P, et al. 4-quinolone signalling in Pseudomonas aeruginosa: old molecules, new perspectives. Int J Med Microbiol 2006; 296: 83–91.

43 Pearson J, Van Delden C, Igleswski B. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol 1999; 181: 1203–1210.

44 Mashburn LM, Whiteley M. Membrane vesicles traffic signals and facilitate group activities in a prokaryote. Nature 2005; 437: 422–425.

45 Williams P, Câmara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009; 12: 182–191.

46 Bjarnsholt T, Jensen P, Burmølle M, et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005; 151: 373–383.

47 Davies D, Parsek M, Pearson J, et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295–298.

48 Diggle S, Winzer K, Chhabra S, et al. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol 2003; 50: 29–43.

49 Christensen L, Moser C, Jensen P, et al. Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology 2007; 153: 2312–2320.

50 Dong Y, Wang L, Zhang L. Quorum-quenching microbial infections: mechanisms and implications. Philos Trans R Soc Lond B Biol Sci 2007; 362: 1201–1211.

51 Chambers CE, Visser MB, Schwab U, et al. Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett 2005; 244: 297–304.

52 Middleton B, Rodgers H, Câmara M, et al. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 207: 1–7.

53 Fulghesu L, Giallorenzo C, Savoia D. Evaluation of different compounds as quorum sensing inhibitors in Pseudomonas aeruginosa. J Chemother 2007; 19: 388–391.

54 Smith K, Bu Y, Suga H. Library screening for synthetic agonists and antagonists of a Pseudomonas aeruginosa autoinducer. Chem Biol 2003; 10: 563–571.

55 Bjarnsholt T, Jensen P, Rasmussen T, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 2005; 151: 3873–3880.

56 Smyth AR, Cifelli PM, Ortori CA, et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomized controlled trial. Pediatr Pulmonol 2010; 45: 356–362.
REVIEW: CYSTIC FIBROSIS

64 Skindersoe M, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 52: 3648–3663.

65 Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in C57/12 mice. Antimicrob Agents Chemother 2007; 51: 3677–3687.

66 Diggle S, Stacey R, Dodd C, et al. The galactophilic lectin, LeCA, contributes to biofilm development in Pseudomonas aeruginosa. Environ Microbiol 2006; 8: 1095–1104.

67 Kadam RU, Bergmann M, Hurley M, et al. A glycopeptide dendrimer inhibitor of the galactose-specific lectin LeCA and of Pseudomonas aeruginosa biofilms. Angew Chem Int Ed Engl 2011; 50: 10631–10635.

68 Johansson E, Crusz S, Kolomiets E, et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LeCb. Chem Biol 2008; 15: 1249–1257.

69 Hauber H, Schulz M, Pforte A, et al. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int J Med Sci 2008; 5: 371–376.

70 Kolomiets E, Swiderska MA, Kadam RU, et al. Glycopeptide dendrimers with high affinity for the fucose-binding lectin LeCb from Pseudomonas aeruginosa. Chem Med Chem 2009; 4: 562–569.

71 Mateos F, Brock JH, Pérez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax 1998; 53: 594–600.

72 Reid DW, Carroll V, O’May C, et al. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J 2007; 30: 286–292.

73 Martin LW, Reid DW, Sharple J, et al. Pseudomonas side-rophores in the sputum of patients with cystic fibrosis. BioMetals 2011; 24: 1059–1067.

74 Meyer JM, Neely A, Stintzi A, et al. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 1996; 64: 518–523.

75 Singh PK, Parsek MR, Greenberg EP, et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552–555.

76 Xiao R, Kisaalita WA. Iron acquisition from transferrin and lactoferrin by Pseudomonas aeruginosa pyoverdin. Microbiology 1997; 143: 2509–2515.

77 Britigan BE, Hayek MB, Doebbeling BN, et al. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun 1993; 61: 5049–5055.

78 Lamont IL, Konings AF, Reid DW. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. BioMetals 2009; 22: 53–60.

79 Moreau-Marquis S, O’Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 2009; 41: 305–313.

80 Piddock L. Multidrug-resistance efflux pumps – not just for resistance. Nat Rev Microbiol 2006; 4: 629–636.

81 Zhang L, Mah T. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 2008; 190: 4447–4452.

82 Hocquet D, Roussel-Devalleze M, Cavallo J-D, et al. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother 2007; 51: 1582–1583.

83 Sanchez P, Linares JF, Ruiz-Diez B, et al. Fitness of in vitro selected Pseudomonas aeruginosa nald and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002; 50: 657–664.
104 Baer M, Sawa T, Flynn P, et al. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. *Infect Immun* 2009; 77: 1083–1090.

105 Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. *Am J Respir Crit Care Med* 2007; 175: 174–183.

106 Georgi E, Le Guellec S, Vecellio L, et al. Feasibility study of OSCN- and lactoferrin (Meveol) nebulization for cystic fibrosis patients. *J Cystic Fibros* 2011; 10: Suppl. 1, S18.

107 Mahamoud A, Chevalier J, Alibert-Franco S, et al. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. *J Antimicrob Chemother* 2007; 59: 1223–1229.